Roche: boosted by broker upgrade
(CercleFinance.com) - Roche's shares are up almost 2% on Thursday, the second winner in Zurich, after Credit Suisse upgraded its rating on the stock to "outperform", having increased their target price for it from 350 Swiss francs to 375 Swiss francs.
Amongst other things, the broker praises the pharmaceutical group's medium-term prospects, which it says are underpinned by a "unique" portfolio of medicines that gives it sound control over its prices, as well as by the capacity to renew its pipeline.
Note that the stock is still down 13% YTD.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
Amongst other things, the broker praises the pharmaceutical group's medium-term prospects, which it says are underpinned by a "unique" portfolio of medicines that gives it sound control over its prices, as well as by the capacity to renew its pipeline.
Note that the stock is still down 13% YTD.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.